Pediatric Endocrinology · GHSR Deficiency

Treatment Options: What is Known About Growth Hormone Therapy

At a Glance

For some children with GHSR deficiency, recombinant human growth hormone may bypass the faulty receptor and improve growth. Small studies report average height gains, but treatment requires pediatric endocrinology supervision, regular monitoring, and individualized insurance review.

For many families, the most important question after a diagnosis of GHSR deficiency is: “Can we treat this?” While this condition is rare and there is no universally established GHSR-specific protocol, the evidence from limited observational studies suggests that recombinant human Growth Hormone (rhGH) therapy is considered a treatment option for some children.

The Logic Behind Treatment

It may seem counterintuitive to give growth hormone to a child who “passed” their growth hormone stimulation test. However, as discussed on the diagnosis page, those tests only measure a “forced” burst of hormone ^[1].

The GHSR receptor is responsible for the body’s natural, daily growth signals. Because that receptor is faulty, your child’s body does not produce enough of its own natural growth hormone pulses to reach a typical height ^[2]^[3]. By providing rhGH (exogenous growth hormone), doctors can bypass the broken receptor and deliver the growth signals directly to the body, restoring growth and increasing the levels of IGF-1 in the blood ^[4]^[2].

What the Research Shows: Limited-Study Averages

The evidence for treating GHSR deficiency comes from specialized case studies. While the number of patients studied is small, the results have been encouraging. These are limited-study averages, not expected results for every child:

Year 1: In the largest study of children with this genetic variant, those treated with rhGH gained an average of 0.9 SDS in height during their first year ^[2].
Year 2: After two years of treatment, the average height gain increased to 1.5 SDS ^[2].
Long-term: Another small study followed children with GHSR variants for several years and found a total height gain of approximately 1.8 SDS ^[5].

These gains mean that many children are able to “catch up” toward the typical growth curve for their age, though final adult heights are still being studied.

Safety and Risks of rhGH Therapy

Treatment requires strict supervision by a pediatric endocrinologist. Doses must never be changed independently. Families must be aware of major safety issues and warning signs.

Seek prompt medical attention if your child experiences:

Severe headache or visual changes: These can be signs of raised intracranial pressure (intracranial hypertension).
Hip or knee pain, or a limp: These can be signs of slipped capital femoral epiphysis (SCFE), a serious hip condition.
Significant joint or muscle pain, or swelling (edema).
Sleep-disordered breathing or severe abdominal pain.

Additionally, rhGH therapy can cause glucose intolerance (affecting how the body handles sugar) and may worsen pre-existing scoliosis.

Contraindications: rhGH is not used in children with active malignancies (cancer), critical illnesses, or those whose growth plates have already closed.

Navigating Insurance and Access

Because GHSR deficiency is not yet a “standard” named indication for growth hormone in many countries, getting treatment approved can be a challenge.

Classification: In the United States, your doctor may need to request coverage under the category of Idiopathic Short Stature (ISS), which is an FDA-approved use for growth hormone ^[6]^[7].
Challenges: In Europe and other regions, ISS is not always an approved indication, which may make access more difficult ^[6].
The Genetic Advantage: Having a confirmed GHSR variant can help your doctor argue for “medical necessity,” showing that your child has a specific biological reason for their short stature rather than just being naturally small ^[8]^[9]. However, U.S. ISS coverage rules are product- and eligibility-specific, and a known genetic cause does not guarantee coverage.

Monitoring During Treatment

Once your child starts rhGH therapy, they will need regular monitoring by a pediatric endocrinologist (usually every 3 to 6 months) to ensure the treatment is safe and effective ^[10]^[11].

IGF-1 Levels: Adjusting the dose is complex; it is not simply “low means increase.” Your doctor will use age-, sex-, and pubertal-stage-adjusted IGF-1 levels alongside clinical findings to find the safest, most effective dose ^[12]^[13].
Thyroid Function: Growth hormone can sometimes affect thyroid hormone levels. Your doctor will check Free T4 and TSH periodically ^[14]^[15].
Glucose and Insulin: While rare, GH therapy can sometimes affect how the body handles sugar. Monitoring fasting glucose or insulin levels is common ^[16]^[17].
Bone Age X-rays: These are repeated periodically to see if the treatment is causing the bones to mature too quickly, which could shorten the total time left for growth ^[18]^[19].

A Note on Appetite

It is important to remember that rhGH therapy replaces growth hormone, but it does not fix the broken ghrelin receptor in the brain.

While some children may experience a slight increase in appetite as they begin to grow faster, the treatment is not a cure for the low appetite or “failure to thrive” seen in some cases ^[2]^[20]. If your child has significant feeding difficulties, they may still require separate nutritional support or consultation with a dietitian alongside their growth hormone shots ^[2].

Common questions in this guide

Can growth hormone help my child with GHSR deficiency if the stimulation test was normal?

It may be an option for some children. A growth hormone stimulation test measures a forced burst of hormone, while GHSR deficiency can reduce the body's normal daily growth signals; recombinant human growth hormone may bypass the faulty receptor and increase a growth-related blood marker called IGF-1. A pediatric endocrinologist must decide whether treatment is appropriate.

What height improvement has been seen with growth hormone treatment for GHSR deficiency?

Small studies, which do not predict results for every child, reported an average gain of 0.9 standardized height score in the first year, 1.5 after two years, and about 1.8 over several years. These numbers describe movement toward the typical growth curve rather than a guaranteed final adult height. Doctors use each child's response and growth pattern to set individual expectations.

What warning signs should I watch for while my child receives growth hormone?

Seek prompt medical attention for severe headache or vision changes, hip or knee pain, or a new limp. Significant joint or muscle pain, swelling, sleep-disordered breathing, or severe abdominal pain also needs medical review. Do not change the dose without the prescribing clinician.

What tests and follow-up are needed during rhGH treatment?

Children usually see a pediatric endocrinologist every three to six months. Monitoring may include IGF-1, thyroid tests such as free T4 and TSH, glucose or insulin, and periodic bone-age X-rays. The clinician uses these results along with growth and pubertal stage to adjust the dose safely.

Will growth hormone therapy improve my child's appetite?

Not necessarily. Growth hormone may slightly increase appetite in some children as growth speeds up, but it does not repair the faulty ghrelin receptor involved in appetite. Significant feeding difficulty or poor weight gain may still require nutritional support or help from a dietitian.

How can families obtain insurance coverage for GHSR deficiency treatment?

Coverage varies by country, insurer, product, and eligibility rules because GHSR deficiency is not a universally named indication. In the United States, a clinician may request coverage under the FDA-approved use for idiopathic short stature, while a confirmed GHSR variant can help explain medical necessity. A genetic result does not guarantee approval, and an appeal may be needed.

Get notified when new evidence is published on Short stature due to GHSR deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

Recombinant human growth hormone may be considered for some children despite a normal stimulation test because the test may not reflect their daily growth signals.
Limited studies reported average height gains of 0.9 standardized height score in the first year, 1.5 after two years, and about 1.8 over several years; individual results vary.
Treatment requires pediatric endocrinologist supervision with regular checks of IGF-1, thyroid function, glucose or insulin, and bone age.
Severe headache or vision changes, hip or knee pain or a limp, swelling, sleep-disordered breathing, or severe abdominal pain require prompt medical attention.
GHSR-specific insurance coverage is not universal; U.S. requests may be considered under idiopathic short stature, but approval rules vary and genetic confirmation does not guarantee coverage.

References (20)

1
Differential Diagnosis of the Short IGF-I-Deficient Child with Apparently Normal Growth Hormone Secretion.
Wit JM, Joustra SD, Losekoot M, et al.
Hormone research in paediatrics 2021; (94(3-4)):81-104 doi:10.1159/000516407.
PMID: 34091447
2
Loss-of-Function GHSR Variants Are Associated With Short Stature and Low IGF-I.
Punt LD, Kooijman S, Mutsters NJM, et al.
The Journal of clinical endocrinology and metabolism 2025; (110(5)):e1303-e1314 doi:10.1210/clinem/dgaf010.
PMID: 39785833
3
Effect of Growth Hormone Secretagogue Receptor Deletion on Growth, Pulsatile Growth Hormone Secretion, and Meal Pattern in Male and Female Mice.
Labarthe A, Zizzari P, Fiquet O, et al.
Neuroendocrinology 2022; (112(3)):215-234 doi:10.1159/000516147.
PMID: 33774644
4
Baseline IGFBP - 3 as the Key Element to Predict Growth Response to Growth Hormone and IGF - 1 Therapy in Subjects with Non - GH Deficient Short Stature and IGF - 1 Deficiency.
Perez-Colon S, Lazareva O, Purushothaman R, et al.
International journal of endocrinology and metabolism 2018; (16(3)):e58928 doi:10.5812/ijem.58928.
PMID: 30197657
5
Growth hormone treatment outcomes in children with genetic isolated growth hormone deficiency.
Aouchiche K, Castets S, Oliver Petit I, et al.
European journal of pediatrics 2025; (184(12)):812 doi:10.1007/s00431-025-06661-0.
PMID: 41326671
6
Clinical Indications for Growth Hormone Therapy.
Danowitz M, Grimberg A
Advances in pediatrics 2022; (69(1)):203-217 doi:10.1016/j.yapd.2022.03.005.
PMID: 35985710
7
Long-acting PEGylated growth hormone in children with idiopathic short stature: time to reconsider our diagnostic and treatment policy?
Wit JM, Joustra SD
European journal of endocrinology 2023; (188(1)) doi:10.1093/ejendo/lvac005.
PMID: 36651155
8
Isolated growth hormone deficiency in children with vertically transmitted short stature: What do the genes tell us?
Plachy L, Amaratunga SA, Dusatkova P, et al.
Frontiers in endocrinology 2022; (13()):1102968 doi:10.3389/fendo.2022.1102968.
PMID: 36714562
9
CHALLENGES OF SECURING GROWTH HORMONE COVERAGE FOR IDIOPATHIC SHORT STATURE: REVIEW OF THE 7-YEAR EXPERIENCE AT ONE INSTITUTION.
Chandar MCSR, Kaplowitz PB, Vaidyanathan P
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019; (25(2)):156-160 doi:10.4158/EP-2018-0271.
PMID: 30383493
10
Effects of early recombinant human growth hormone treatment in young Chinese children with Prader-Willi syndrome.
Gao Y, Yang LL, Dai YL, et al.
Orphanet journal of rare diseases 2023; (18(1)):25 doi:10.1186/s13023-023-02615-7.
PMID: 36750945
11
Response to Recombinant Human Growth Hormone (rhGH) Therapy in Children with Growth Hormone Deficiency.
Riaz M, Ibrahim MN, Rai VR, et al.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2024; (34(8)):932-935 doi:10.29271/jcpsp.2024.08.932.
PMID: 39113512
12
Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database.
Kim M, Kim EY, Kim EY, et al.
PloS one 2021; (16(11)):e0259287 doi:10.1371/journal.pone.0259287.
PMID: 34723984
13
The role of IGF1 in determining body composition in children and adolescents with growth hormone deficiency and those with idiopathic short stature.
Zaitoon H, Yackobovitch-Gavan M, Midlej E, et al.
Endocrine 2024; (86(3)):1110-1120 doi:10.1007/s12020-024-03992-0.
PMID: 39143422
14
Decreased Thyroxine Levels during rhGH Therapy in Children with Growth Hormone Deficiency.
Witkowska-Sędek E, Kucharska AM, Rumińska M, et al.
Journal of clinical medicine 2021; (10(21)) doi:10.3390/jcm10215100.
PMID: 34768618
15
Thyroid function in children with growth hormone deficiency during long-term growth hormone replacement therapy.
Witkowska-Sędek E, Borowiec A, Majcher A, et al.
Central-European journal of immunology 2018; (43(3)):255-261 doi:10.5114/ceji.2018.80043.
PMID: 30588169
16
Biological effects of recombinant human growth hormone therapy on metabolism in children with growth hormone deficiency: a review.
Dyrka K, Łachut K, Kolesińska Z, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2025; (38(8)):796-806 doi:10.1515/jpem-2025-0057.
PMID: 40320660
17
Efficacy and safety of recombinant human growth hormone in treating Chinese children with idiopathic short stature.
Ying YQ, Hou L, Liang Y, et al.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2018; (42-43()):80-85 doi:10.1016/j.ghir.2018.09.003.
PMID: 30343148
18
Factors affecting bone age maturation during 3 years of growth hormone treatment in patients with idiopathic growth hormone deficiency and idiopathic short stature: Analysis of data from the LG growth study.
Kang MJ, Kim EY, Shim YS, et al.
Medicine 2019; (98(14)):e14962 doi:10.1097/MD.0000000000014962.
PMID: 30946320
19
Predictors of Response to Growth Hormone Therapy in Children with Idiopathic Growth Hormone Deficiency: A Narrative Review.
Cammisa I, De Fortuna G, Rulli E, et al.
Children (Basel, Switzerland) 2026; (13(4)) doi:10.3390/children13040545.
PMID: 42073123
20
The benefit of rhGH therapy in a Chinese child with 12q14 microdeletion syndrome: a case report.
Ping Y, Luo L, Chen Y, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2023; (36(8)):798-802 doi:10.1515/jpem-2023-0060.
PMID: 37283093

This page is for informational purposes only and does not constitute medical advice about growth hormone therapy for GHSR deficiency. A pediatric endocrinologist should guide your child's treatment, monitoring, safety decisions, and insurance documentation.